Option Care Health, Inc. offers home and alternate site infusion services in the United States.
$31.65+0.48%
报价 2026-11-06
市值
$4.74B
EV
$5.73B
PE (TTM)
23.4x
预期 PE (FY2026)
16.8x
52 周区间距高点 -13.5%
$19.52$36.59
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-07未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.1x | 1.80 → 2.08（1.2x） | 15.2 |
| FY+32028-12 | 1.2x | 1.80 → 2.32（1.3x） | 13.6 |
毛利率 18% · TTM 收入 $5752M · 基数 EPS 1.80（调整后）
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| OPCHOption Care Health, Inc. | $4.74B | +0.5% | +2.0% | 18.5% | 23.4x | 13.8x | 13.4x | |
| KYMRKymera Therapeutics, Inc. | $11.25B | +2.8% | +48.6% | 100% | – | – | – | |
| HNGEHinge Health, Inc. | $9.34B | -0.2% | +52.9% | 87% | 55.7x | 55.8x | 29.3x | 高增长 |
| OSCROscar Health, Inc. | $7.95B | -7.6% | +55.7% | 100% | 19.9x | 8.2x | 2.0x | 高增长 |
| LNTHLantheus Holdings, Inc. | $6.57B | -0.1% | -2.3% | 61.1% | 21.3x | 13.2x | 18.6x | |
| IMVTImmunovant, Inc. | $6.31B | +7.5% | -37.1% | 0% | – | – | – | |
| ACADACADIA Pharmaceuticals Inc. | $3.66B | -0.0% | +14.8% | 91.7% | 9.1x | 26.3x | 34.6x | |
| TMDXTransMedics Group, Inc. | $3.06B | +27.9% | +23.8% | 58.5% | 21.0x | 24.7x | 68.5x | GARP |
| ADMAADMA Biologics, Inc. | $2.85B | -3.6% | +11.7% | 68.5% | 16.7x | 12.0x | 22.3x | |
| 同行中位数 | – | – | +19.3% | 77.7% | 20.4x | 19.0x | 25.8x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 | 2024-09-30 Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.44B | $1.35B | $1.47B | $1.44B | $1.42B | $1.33B | $1.35B | $1.28B |
| Gross Margin | 18.5% | 18.3% | 18% | 17.9% | 17.9% | 18.6% | 19.9% | 20.1% |
| Operating Margin | 5.9% | 5.7% | 6.2% | 5.9% | 5.8% | 5.9% | 6.5% | 6.7% |
| Net Income | $53.9M | $45.3M | $58.5M | $51.8M | $50.5M | $46.7M | $60.1M | $53.9M |
| Diluted EPS | 0.35 | 0.29 | 0.37 | 0.32 | 0.31 | 0.28 | 0.35 | 0.31 |
| Operating Cash Flow | $183.6M | $-12.1M | $35.9M | $139.4M | $90.3M | $-7.2M | $36.1M | $160.4M |